Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
The Lost Immunological Innocence of Biological Scaffolds for TAVI
24 Pages Posted: 8 Oct 2020
More...
There are 3 versions of this paper
The Lost Immunological Innocence of Biological Scaffolds for TAVI
The Lost Immunological Innocence of Biological Scaffolds for TAVI
Abstract
Background: Transcatheter aortic valve implantation (TAVI) is rapidly replacing cardiac surgery due to its minimal invasiveness and practicability. Midterm immunological studies on the biocompatibility of galactose-alpha-1,3-galactose (α - Gal)-carrying bioprosthetic heart valves (BHVs) for TAVI are not available. In this study we investigated whether BHVs employed for TAVI augment an α - Gal-specific antibody-dependent and antibody-independent immune response 3 months post TAVI.
Methods: This prospective observational study included 27 patients with severe aortic valve stenosis undergoing TAVI and 10 patients with severe mitral valve regurgitation treated with a transcatheter MitraClip procedure. Serum samples were collected before and 90 days after treatment and analyzed for concentrations of α - Gal-specific IgG, IgG subclasses and IgE, complement C3a, NETosis specific CitH3, and the systemic inflammation markers sST2 and IL-33 via ELISA.
Findings: Three months after TAVI we found significantly increased serum concentrations of α - Gal-specific IgG3, C3a, citH3 levels, and sST2 (p=0·002, p=0·001, p=0·025, and p=0·039, respectively). Sensitization of α - Gal-specific IgE antibodies occurred in 55% of all patients after TAVI.
Interpretation: Our results indicate that TAVI elicits a specific humoral immune response against α - Gal and causes an unspecific humoral inflammation compared with patients undergoing MitraClip implantation. This observation will lead to a better understanding of post intervention morbidity and the long-term durability of bioprostheses and indicates that caution is appropriate when designing implantation strategies for younger patients.
Funding Statement: This work was supported by the institutional surgical research facility ARGE Ankersmit (FOLAB Chirurgie)
Declaration of Interests: None of the authors have any conflict of interest to declare.
Ethics Approval Statement: Ethics approval was obtained from the Institutional Ethics Committee of the Medical University of Vienna (EK 2218/2016). All experiments were performed in accordance with the approved ethical guidelines. Written informed consent was obtained from all study participants.
Keywords: TAVI, biological scaffolds, aortic valve disease, MitraClip, Alpha-Gal, complement, NETosis, sST2/IL-33
Suggested Citation: Suggested Citation